Clinical Trial Detail

NCT ID NCT02223598
Title A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cleave Biosciences, Inc.
Indications

multiple myeloma

hematologic cancer

Therapies

CB-5083

CB-5083 + Dexamethasone

Age Groups: adult senior

No variant requirements are available.